drugset / Trial / NCT05324449
Epidiolex® for Anxiety in Pediatric Epilepsy
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective open label study assessing the efficacy and tolerability of pharmaceutical grade cannabidiol--Epidiolex (R), for the treatment of anxiety in pediatric patients with pediatric epilepsy that has been difficult to treat and requires ongoing use of anticonvulsant medication.
Timeline
- Start
- 2022-04-05
- Primary completion
- 2025-03-17
- Completion
- 2025-05-05
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 100 mg/ml | — |